Medication-related osteonecrosis of the jaw: prevention, diagnosis and management in patients with cancer and bone metastases
Patients with cancer that has metastasized to bone and individuals with osteoporosis are at risk of developing skeletal complications, including fractures, which can lead to pain, decreased quality of life (QoL) and lengthy stays in hospital [1 –5]. High-dose regimens of bisphosphonates (such as zoledronic acid 4 mg every 3–4 weeks intravenously [5]) and the monoclonal antibody denosumab (an agent that targets receptor activator of nuclear factor kappa B ligand [RANKL]; 120 mg every 4weeks subcutaneously [SC]) are approved for the prev ention of skeletal-related events (SREs) in adults with advanced malignancies involving bone; low-dose regimens (such as zoledronic acid 5 mg yearly IV; denosumab 60 mg every 6 months SC) are approved for the treatment of osteoporosis [6–9].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Sven Otto, Christoph Pautke, Tim Van den Wyngaert, Daniela Niepel, Morten Schi ødt Tags: General and Supportive Care Source Type: research
More News: Cancer | Cancer & Oncology | Hospitals | Orthopaedics | Osteoporosis | Pain | Pain Management | Reclast | Xgeva | Zometa